导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.97% | 4093/4773 |
| 近一周 | -2.46% | 2241/5462 |
| 近一月 | -0.30% | 775/5421 |
| 近一季 | -1.45% | 1006/5209 |
| 近半年 | -6.43% | 3083/4920 |
| 近一年 | -11.33% | 3495/4366 |
| 近两年 | 31.49% | 2219/2954 |
| 近三年 | 16.79% | 1591/2253 |
| 成立以来 | 10.55% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.60% 4720/4961 |
1.18% 3069/5312 |
- - |
- - |
| 2025 | 12.65% 2683/4813 |
-5.68% 3311/3635 |
6.83% 418/4076 |
6.02% 3558/4524 |
5.45% 443/4813 |
| 2024 | 35.40% 57/3463 |
-2.68% 1407/2808 |
-3.19% 1318/3014 |
42.23% 55/3129 |
1.05% 1128/3463 |
| 2023 | -3.01% 621/2656 |
0.93% 1671/2280 |
-0.07% 360/2385 |
5.49% 87/2515 |
-8.84% 2312/2655 |
| 2022 | -17.17% 557/2207 |
-14.80% 1001/1919 |
2.81% 1257/2016 |
-13.92% 996/2113 |
9.84% 195/2208 |
| 2021 | -14.30% 1146/1822 |
-11.12% 1128/1255 |
-2.02% 1191/1330 |
-3.93% 671/1466 |
2.44% 595/1822 |
| 2020 | 11.71% 822/1250 |
-14.32% 959/1028 |
8.66% 819/1067 |
14.46% 275/1164 |
4.84% 828/1184 |
| 2019 | - - |
- - |
- - |
- - |
4.57% 798/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 易方达沪深300非银联接C VS. 长安沪深300非周期A(740101) |